Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Using Data Science to Provide Preliminary Estimates of Out-of-Hospital Cardiac Arrest in Rural South Dakota.

Samra HA, Sudhagoni RG, Kupershmidt S, Seiber MJ, Fuller MD, Pickthorn ST, Lowmiller K.

S D Med. 2018 Feb;71(2):72-79.

PMID:
29990416
2.

The Selective Nav1.7 Inhibitor, PF-05089771, Interacts Equivalently with Fast and Slow Inactivated Nav1.7 Channels.

Theile JW, Fuller MD, Chapman ML.

Mol Pharmacol. 2016 Nov;90(5):540-548. Epub 2016 Sep 1.

PMID:
27587537
3.

A novel selective and orally bioavailable Nav 1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability.

Payne CE, Brown AR, Theile JW, Loucif AJ, Alexandrou AJ, Fuller MD, Mahoney JH, Antonio BM, Gerlach AC, Printzenhoff DM, Prime RL, Stockbridge G, Kirkup AJ, Bannon AW, England S, Chapman ML, Bagal S, Roeloffs R, Anand U, Anand P, Bungay PJ, Kemp M, Butt RP, Stevens EB.

Br J Pharmacol. 2015 May;172(10):2654-70. doi: 10.1111/bph.13092. Epub 2015 Apr 10.

4.

Differential regulation of CaV1.2 channels by cAMP-dependent protein kinase bound to A-kinase anchoring proteins 15 and 79/150.

Fuller MD, Fu Y, Scheuer T, Catterall WA.

J Gen Physiol. 2014 Mar;143(3):315-24. doi: 10.1085/jgp.201311075.

5.

Persistence and origin of the lunar core dynamo.

Suavet C, Weiss BP, Cassata WS, Shuster DL, Gattacceca J, Chan L, Garrick-Bethell I, Head JW, Grove TL, Fuller MD.

Proc Natl Acad Sci U S A. 2013 May 21;110(21):8453-8. doi: 10.1073/pnas.1300341110. Epub 2013 May 6.

6.

A long-lived lunar core dynamo.

Shea EK, Weiss BP, Cassata WS, Shuster DL, Tikoo SM, Gattacceca J, Grove TL, Fuller MD.

Science. 2012 Jan 27;335(6067):453-6. doi: 10.1126/science.1215359.

7.

Molecular mechanism of calcium channel regulation in the fight-or-flight response.

Fuller MD, Emrick MA, Sadilek M, Scheuer T, Catterall WA.

Sci Signal. 2010 Sep 28;3(141):ra70. doi: 10.1126/scisignal.2001152.

8.

Isolation and characterization of a high affinity peptide inhibitor of ClC-2 chloride channels.

Thompson CH, Olivetti PR, Fuller MD, Freeman CS, McMaster D, French RJ, Pohl J, Kubanek J, McCarty NA.

J Biol Chem. 2009 Sep 18;284(38):26051-62. doi: 10.1074/jbc.M109.031724. Epub 2009 Jul 1.

9.

State-dependent inhibition of cystic fibrosis transmembrane conductance regulator chloride channels by a novel peptide toxin.

Fuller MD, Thompson CH, Zhang ZR, Freeman CS, Schay E, Szakács G, Bakos E, Sarkadi B, McMaster D, French RJ, Pohl J, Kubanek J, McCarty NA.

J Biol Chem. 2007 Dec 28;282(52):37545-55. Epub 2007 Oct 19.

10.

Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.

Cihlar T, Ray AS, Laflamme G, Vela JE, Tong L, Fuller MD, Roy A, Rhodes GR.

Antivir Ther. 2007;12(2):267-72.

PMID:
17503669
11.

Mechanism of active renal tubular efflux of tenofovir.

Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, Rhodes GR.

Antimicrob Agents Chemother. 2006 Oct;50(10):3297-304.

12.

Inhibition of ClC-2 chloride channels by a peptide component or components of scorpion venom.

Thompson CH, Fields DM, Olivetti PR, Fuller MD, Zhang ZR, Kubanek J, McCarty NA.

J Membr Biol. 2005 Nov;208(1):65-76.

PMID:
16596447
13.

The block of CFTR by scorpion venom is state-dependent.

Fuller MD, Zhang ZR, Cui G, McCarty NA.

Biophys J. 2005 Dec;89(6):3960-75. Epub 2005 Sep 23.

14.

Structure elucidation of neutral, di-, tri-, and tetraglycosylceramides from High Five cells: identification of a novel (non-arthro-series) glycosphingolipid pathway.

Fuller MD, Schwientek T, Wandall HH, Pedersen JW, Clausen H, Levery SB.

Glycobiology. 2005 Dec;15(12):1286-301. Epub 2005 Jul 13.

PMID:
16014747
15.

CFTR: a cysteine at position 338 in TM6 senses a positive electrostatic potential in the pore.

Liu X, Zhang ZR, Fuller MD, Billingsley J, McCarty NA, Dawson DC.

Biophys J. 2004 Dec;87(6):3826-41. Epub 2004 Sep 10.

16.

Inhibition of CFTR channels by a peptide toxin of scorpion venom.

Fuller MD, Zhang ZR, Cui G, Kubanek J, McCarty NA.

Am J Physiol Cell Physiol. 2004 Nov;287(5):C1328-41. Epub 2004 Jul 7.

17.

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.

Miller MD, Margot NA, Lamy PD, Fuller MD, Anton KE, Mulato AS, Cherrington JM.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):450-8.

PMID:
11511821
18.

The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.

Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH.

Mol Pharmacol. 1999 Sep;56(3):570-80.

PMID:
10462545
19.

In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.

Cherrington JM, Fuller MD, Lamy PD, Miner R, Lalezari JP, Nuessle S, Drew WL.

J Infect Dis. 1998 Dec;178(6):1821-5.

PMID:
9815243
20.
21.

Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.

Miller MD, Lamy PD, Fuller MD, Mulato AS, Margot NA, Cihlar T, Cherrington JM.

Mol Pharmacol. 1998 Aug;54(2):291-7.

PMID:
9687570
23.

In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir).

Xiong X, Flores C, Fuller MD, Mendel DB, Mulato AS, Moon K, Chen MS, Cherrington JM.

Antiviral Res. 1997 Nov;36(2):131-7.

PMID:
9443670
25.

High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes.

Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA.

J Infect Dis. 1997 Jul;176(1):69-77. Erratum in: J Infect Dis 1998 Apr;177(4):1140-1.

PMID:
9207351
26.
27.

Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases.

Cherrington JM, Fuller MD, Mulato AS, Allen SJ, Kunder SC, Ussery MA, Lesnikowski Z, Schinazi RF, Sommadossi JP, Chen MS.

Antimicrob Agents Chemother. 1996 May;40(5):1270-3.

28.

Tetrapyrrole utilization of Bacteroides fragilis.

Fuller MD, Caldwell DR.

Can J Microbiol. 1982 Dec;28(12):1304-10.

PMID:
7168828

Supplemental Content

Loading ...
Support Center